[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100478031":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":17,"locations":23,"responsibleParty":41,"collaborators":43,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":7,"eligibilityCriteria":52,"healthyVolunteers":49,"sex":53,"minAge":54,"maxAge":7,"enrollmentInfo":55,"targetDuration":7,"studyType":58,"phases":7,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":25,"whyStopped":7,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Baptist Health South Florida","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"Observational study","It takes the patient on average 15 minutes to complete the Brainlab Cognition app.",[13],{"name":14,"affiliation":15,"role":16},"Rupesh R Kotecha, MD","Miami Cancer Institute","PRINCIPAL_INVESTIGATOR",[18],{"name":19,"role":20,"phone":21,"phoneExt":7,"email":22},"Rupesh R Kotecha","CONTACT","17865962000","rupeshk@baptisthealth.net",[24],{"facility":15,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"RECRUITING","Miami","Florida","33176","United States","US",{"type":32,"coordinates":33},"Point",[34,35],-80.19366,25.77427,{"lat":35,"lon":34},[38],{"name":39,"role":20,"phone":40,"phoneExt":7,"email":22},"Rupesh Kotecha","786-596-2000",{"type":42,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[44],{"name":45,"class":46},"Brainlab AG","INDUSTRY","100478031","integration-of-neurocognitive-biomarkers-into-a-neuro-oncology-clinic-100478031",false,"NCT05504681","Integration of Neurocognitive Biomarkers Into a Neuro-Oncology Clinic","Inclusion Criteria:\n\n1. All adult (18+) patients with central nervous system (CNS) tumors, both primary brain malignancies and brain metastases, treated with radiotherapy (partial brain, stereotactic radiosurgery, stereotactic fractionated radiotherapy, or whole-brain radiotherapy), surgery, and\u002For antineoplastic therapy and followed thereafter at Miami Cancer Institute (MCI)\n2. Life expectancy ≥ 6 months\n3. Willingness to participate in ongoing registration study\n\nExclusion Criteria:\n\n1. Patients receiving radiotherapy to the brain for functional disease (arteriovenous malformations, trigeminal neuralgia, essential tremors, etc.)\n2. Pediatric patients (\\\u003C18 years old), pregnant women, and prisoners.","ALL","18 Years",{"count":56,"type":57},200,"ESTIMATED","OBSERVATIONAL","This is prospective observational registry study that will assess 1) if the neurocognitive function app (Brainlab Cognition) can be used in a widespread neuro-oncology clinic setting and 2) if patient reported quality of life parameters can be obtained electronically and integrated into clinic.",[61],"Neurocognitive Disorders",[63,64],"Neurocognitive","Brainlab Cognition app","2026-05-18",{"date":67,"type":68},"2026-05-19","ACTUAL",{"date":70,"type":68},"2021-11-30",{"date":72,"type":57},"2032-04",{"name":5,"class":6},1]